211 related articles for article (PubMed ID: 22453769)
1. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial.
Powell RJ; Marston WA; Berceli SA; Guzman R; Henry TD; Longcore AT; Stern TP; Watling S; Bartel RL
Mol Ther; 2012 Jun; 20(6):1280-6. PubMed ID: 22453769
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
[TBL] [Abstract][Full Text] [Related]
3. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
Patel AN; Henry TD; Quyyumi AA; Schaer GL; Anderson RD; Toma C; East C; Remmers AE; Goodrich J; Desai AS; Recker D; DeMaria A;
Lancet; 2016 Jun; 387(10036):2412-21. PubMed ID: 27059887
[TBL] [Abstract][Full Text] [Related]
4. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
[TBL] [Abstract][Full Text] [Related]
5. Improved amputation-free survival in unreconstructable critical limb ischemia and its implications for clinical trial design and quality measurement.
Benoit E; O'Donnell TF; Kitsios GD; Iafrati MD
J Vasc Surg; 2012 Mar; 55(3):781-9. PubMed ID: 22209608
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.
Losordo DW; Kibbe MR; Mendelsohn F; Marston W; Driver VR; Sharafuddin M; Teodorescu V; Wiechmann BN; Thompson C; Kraiss L; Carman T; Dohad S; Huang P; Junge CE; Story K; Weistroffer T; Thorne TM; Millay M; Runyon JP; Schainfeld R;
Circ Cardiovasc Interv; 2012 Dec; 5(6):821-30. PubMed ID: 23192920
[TBL] [Abstract][Full Text] [Related]
7. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.
Norgren L; Weiss N; Nikol S; Hinchliffe RJ; Lantis JC; Patel MR; Reinecke H; Ofir R; Rosen Y; Peres D; Aberman Z
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):538-545. PubMed ID: 30686676
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy.
Henry TD; Traverse JH; Hammon BL; East CA; Bruckner B; Remmers AE; Recker D; Bull DA; Patel AN
Circ Res; 2014 Sep; 115(8):730-7. PubMed ID: 25142002
[TBL] [Abstract][Full Text] [Related]
9. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites.
Wang SK; Green LA; Gutwein AR; Drucker NA; Babbey CM; Gupta AK; Fajardo A; Motaganahalli RL; Wilson MG; Murphy MP
J Vasc Surg; 2018 Aug; 68(2):560-566. PubMed ID: 29503004
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia.
Chung J; Modrall JG; Ahn C; Lavery LA; Valentine RJ
J Vasc Surg; 2015 Jan; 61(1):162-9. PubMed ID: 25073577
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting with isolated below-the-knee lesions.
Iida O; Soga Y; Hirano K; Kawasaki D; Suzuki K; Miyashita Y; Terashi H; Uematsu M
J Vasc Surg; 2012 Feb; 55(2):363-370.e5. PubMed ID: 22051875
[TBL] [Abstract][Full Text] [Related]
14. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design.
Benoit E; O'Donnell TF; Iafrati MD; Asher E; Bandyk DF; Hallett JW; Lumsden AB; Pearl GJ; Roddy SP; Vijayaraghavan K; Patel AN
J Transl Med; 2011 Sep; 9():165. PubMed ID: 21951607
[TBL] [Abstract][Full Text] [Related]
15. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases.
Ledford KJ; Murphy N; Zeigler F; Bartel RL; Tubo R
Stem Cell Res Ther; 2015 Mar; 6(1):25. PubMed ID: 25889271
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study.
Schiavetta A; Maione C; Botti C; Marino G; Lillo S; Garrone A; Lanza L; Pagliari S; Silvestroni A; Signoriello G; Sica V; Cobellis G
Stem Cells Transl Med; 2012 Jul; 1(7):572-8. PubMed ID: 23197862
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
[TBL] [Abstract][Full Text] [Related]
19. Contemporary management of critical lower limb ischemia in TASC D lesions with subintimal angioplasty in femoro-popliteal lesions, tibial angioplasty and sequential compression biomechanical device for infra-inguinal arterial occlusion. Experience and quality of life outcome learned over 25 years.
Sultan S; Hynes N
J Cardiovasc Surg (Torino); 2014 Dec; 55(6):813-25. PubMed ID: 25216216
[TBL] [Abstract][Full Text] [Related]
20. Lifelong limb preservation: A patient-centered description of lower extremity arterial reconstruction outcomes.
Shean KE; Soden PA; Schermerhorn ML; Zettervall SL; Deery SE; Darling JD; Hamdan A; LoGerfo FW
J Vasc Surg; 2017 Oct; 66(4):1117-1122. PubMed ID: 28502548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
